Clonal Analysis of Human Recurrent Superficial Bladder Cancer by Immunohistochemistry of P53 and Retinoblastoma Proteins

Abstract

No AccessJournal of UrologyInvestigative Urology1 Nov 1996Clonal Analysis of Human Recurrent Superficial Bladder Cancer by Immunohistochemistry of P53 and Retinoblastoma Proteins Herng-Der Chern, Michael J. Becich, Raj A. Persad, Marjorie Romkes, Patrick Smith, Chris Collins, Yi-Hwei Li, and Robert A. Branch Herng-Der ChernHerng-Der Chern , Michael J. BecichMichael J. Becich , Raj A. PersadRaj A. Persad , Marjorie RomkesMarjorie Romkes , Patrick SmithPatrick Smith , Chris CollinsChris Collins , Yi-Hwei LiYi-Hwei Li , and Robert A. BranchRobert A. Branch View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65550-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To investigate the clonal origin of malignant cells in recurrent superficial bladder cancer. Materials and Methods: We compared the protein expression of p53 and retinoblastoma (Rb) by immunohistochemistry using antibody P1801 and PMG3-245, respectively, in 13 patients at the time of primary superficial bladder cancer resection (6 Ta and 7 T1) and their 15 corresponding recurrences of disease. Mutations in p53 and Rb were inferred on the basis of immunoperoxidase staining. Results: At the time of initial tumor resection, a p53 mutation was observed in 5 patients (39 percent) and an Rb mutation was observed in 3 (23 percent). The p53/Rb mutation status of recurrent bladder cancers completely matched their corresponding primary bladder cancer. Conclusions: The chance that recurrent bladder cancer originated from independent clones in this study was extremely small (p less than 10 sup -6). This result strongly supports the monoclonal origin of recurrent superficial bladder cancer. References 1 : Superficial bladder tumors (stage pTa, grade 1 and 2): the importance of recurrence pattern following initial resection. J. Urol.1986; 135: 920. Abstract, Google Scholar 2 : Cancer of the bladder. In: . Philadelphia: J. B. Lippincott1989: 1008. Google Scholar 3 : Clonal origin of bladder cancer. New Engl. J. Med.1992; 326: 737. Crossref, Medline, Google Scholar 4 : Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet1993; 342: 1087. Crossref, Medline, Google Scholar 5 : Role of chromosome 9 in human bladder cancer. Cancer Res.1993; 53: 4066. Medline, Google Scholar 6 : Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res.1994; 54: 784. Medline, Google Scholar 7 : Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst.1992; 84: 1251. Crossref, Medline, Google Scholar 8 : Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst.1992; 84: 1256. Crossref, Medline, Google Scholar 9 : Characterization of a 54 kd cellular SV40 tumor antigen present in SV-40-transformed cells and uninfected embryonal carcinoma cells. Cell1979; 17: 43. Google Scholar 10 : A mammalian cell cycle checkpoint pathway utilizing P53 and GADD45 is defective in ataxia telangiectasia. Cell1992; 71: 587. Google Scholar 11 : P53 function and disfunction. Cell1992; 70: 523. Google Scholar 12 : P53, guardian of the genome. Nature1992; 358: 15. Google Scholar 13 : Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol.1988; 8: 531. Google Scholar 14 : Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst.1993; 85: 53. Crossref, Medline, Google Scholar 15 : Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet1990; 335: 675. Google Scholar 16 : Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer1991; 63: 967. Google Scholar 17 : High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene1992; 7: 1159. Google Scholar 18 : Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn. Mol. Pathol.1993; 2: 4. Google Scholar 19 : p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer1994; 56: 347. Crossref, Medline, Google Scholar 20 : The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature1987; 329: 642. Google Scholar 21 : Association between an oncogene and anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature1988; 334: 124. Google Scholar 22 : The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell1991; 67: 293. Google Scholar 23 : The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. E.M.B.O.J.1991; 10: 4279. Google Scholar 24 : International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer1974; 33: 1484. Google Scholar 25 : Selection and interpretation of diagnostic tests and procedures: principles and applications. Ann. Intern. Med.1981; 84: 453. Google Scholar 26 : A critical test of the role of population density in producing transformation. Proc. Natl. Acad. Sci. U.S.A.1994; 91: 7712. Google Scholar 27 : Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol.1994; 152: 388. Link, Google Scholar 28 : Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int. J. Cancer1993; 53: 365. Google Scholar 29 : Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur. Urol.1992; 21: 126. Google Scholar 30 : Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J. Urol.1992; 147: 738. Link, Google Scholar Center for Clinical Pharmacology, Environmental and Occupational Health and the Departments of Pathology and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania and the Departments of Urology and Pathology, University of Bristol, Bristol, United Kingdom.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byDUGGAN B, GRAY S, McKNIGHT J, WATSON C, JOHNSTON S and WILLIAMSON K (2018) Oligoclonality in Bladder Cancer:: The Implication for Molecular TherapiesJournal of Urology, VOL. 171, NO. 1, (419-425), Online publication date: 1-Jan-2004.DUGGAN B, KELLY J, KEANE P and JOHNSTON S (2018) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, VOL. 165, NO. 3, (946-954), Online publication date: 1-Mar-2001.Montie J, Wojno K, Klein E, Pearsall C and Levin H (2018) TRANSITIONAL CELL CARCINOMA IN SITU OF THE SEMINAL VESICLES: 8 CASES WITH DISCUSSION OF PATHOGENESIS, AND CLINICAL AND BIOLOGICAL IMPLICATIONSJournal of Urology, VOL. 158, NO. 5, (1895-1898), Online publication date: 1-Nov-1997. Volume 156Issue 5November 1996Page: 1846-1849 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Herng-Der Chern More articles by this author Michael J. Becich More articles by this author Raj A. Persad More articles by this author Marjorie Romkes More articles by this author Patrick Smith More articles by this author Chris Collins More articles by this author Yi-Hwei Li More articles by this author Robert A. Branch More articles by this author Expand All Advertisement PDF downloadLoading ...